Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Taylor R Brooks

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
The Pharos of Alpha Omega Alpha-Honor Medical Society. Alpha Omega Alpha|June 23, 2016
Breaking the oath: Why physicians tortureTaylor R Brooks
Leukemia & Lymphoma|July 28, 2023
Conditioning regimens: balancing efficacy and toxicityTaylor R Brooks, Deepa Jagadeesh
Blood Reviews|November 10, 2023
A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphomaTaylor R Brooks, Paolo F Caimi
Breast Cancer Research and Treatment|July 6, 2013
Myeloid-derived suppressor cells in breast cancerJoseph Markowitz, Robert Wesolowski, Tracey Papenfuss, et al.
Nature Communications|February 28, 2015
Generation of cellular immune memory and B-cell immunity is impaired by natural killer cellsCarolyn Rydyznski, Keith A Daniels, Erik P Karmele, et al.
Cancer Immunology, Immunotherapy : CII|October 12, 2014
Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of diseaseJoseph Markowitz, Taylor R Brooks, Megan C Duggan, et al.
Current Opinion in Virology|November 23, 2015
Roles of natural killer cells in antiviral immunityStephen N Waggoner, Seth D Reighard, Ivayla E Gyurova, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 10, 2013
A phase I trial of bortezomib and interferon-α-2b in metastatic melanomaJoseph Markowitz, Eric A Luedke, Valerie P Grignol, et al.
Cancer Immunology, Immunotherapy : CII|February 7, 2019
A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanomaLorena P Suarez-Kelly, Kala M Levine, Thomas E Olencki, et al.
Scientific Reports|November 15, 2017
Nitric oxide mediated inhibition of antigen presentation from DCs to CD4<sup>+</sup> T cells in cancer and measurement of STAT1 nitrationJoseph Markowitz, Jiang Wang, Zach Vangundy, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
The Pharos of Alpha Omega Alpha-Honor Medical Society. Alpha Omega Alpha|June 23, 2016
Breaking the oath: Why physicians tortureTaylor R Brooks
Leukemia & Lymphoma|July 28, 2023
Conditioning regimens: balancing efficacy and toxicityTaylor R Brooks, Deepa Jagadeesh
Blood Reviews|November 10, 2023
A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphomaTaylor R Brooks, Paolo F Caimi
Breast Cancer Research and Treatment|July 6, 2013
Myeloid-derived suppressor cells in breast cancerJoseph Markowitz, Robert Wesolowski, Tracey Papenfuss, et al.
Nature Communications|February 28, 2015
Generation of cellular immune memory and B-cell immunity is impaired by natural killer cellsCarolyn Rydyznski, Keith A Daniels, Erik P Karmele, et al.
Cancer Immunology, Immunotherapy : CII|October 12, 2014
Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of diseaseJoseph Markowitz, Taylor R Brooks, Megan C Duggan, et al.
Current Opinion in Virology|November 23, 2015
Roles of natural killer cells in antiviral immunityStephen N Waggoner, Seth D Reighard, Ivayla E Gyurova, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 10, 2013
A phase I trial of bortezomib and interferon-α-2b in metastatic melanomaJoseph Markowitz, Eric A Luedke, Valerie P Grignol, et al.
Cancer Immunology, Immunotherapy : CII|February 7, 2019
A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanomaLorena P Suarez-Kelly, Kala M Levine, Thomas E Olencki, et al.
Scientific Reports|November 15, 2017
Nitric oxide mediated inhibition of antigen presentation from DCs to CD4<sup>+</sup> T cells in cancer and measurement of STAT1 nitrationJoseph Markowitz, Jiang Wang, Zach Vangundy, et al.
Pageof 2